ClinicalTrials.gg
Active, not recruitingNCT02586857Updated Mar 25, 2026Results posted

A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)

A Phase 1/2 interventional study of ACP-196 in Glioblastoma Multiforme, sponsored by Acerta Pharma BV. Active, not recruiting at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-25.

Sponsored by Acerta Pharma BV (part of AstraZeneca) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,302 studies in Glioblastoma with a site in United States — 194 open to participants now, 324 under way, 16 of them phase 3. Glioblastoma · United States.

Enrollment
701st of 1,155
24 · median 33
Started
2016
with 51 others
Phase 1/2
190 of 1,302
32 open now
Primary completion
2020-06
later than 4 of 322 live
Registered
713th of 1,302
by date

Among the 1,302 studies in Glioblastoma with a site in United States, this one is the 701st largest by enrollment of the 1,155 interventional ones that give a count, is one of 52 that started in 2016, is one of 190 in phase 1/2, reaches primary completion later than 4 of the 322 other live ones, and was the 713th registered.

Glioblastoma

2,135 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

194 of the 1,302 studies in Glioblastoma with a site in United States are open now. Recruiting first, the newest first:

189 more — sign in →

All 194 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 338 Glioblastoma studies recruiting now, 233 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,302 studies in Glioblastoma with a site in United States, or all of them as a file.
02

Study summary

A Phase 1b/2, Multicenter, Open-Label Study of ACP-196 in Subjects with Recurrent Glioblastoma Multiforme (GBM)

Read the detailed description

A Phase 1b/2, multicenter, open-label study was designed to evaluate the efficacy and safety of acalabrutinib in subjects with recurrent glioblastoma multiforme (GBM) who had progressed after one or two prior systemic treatment regimens.

03

Conditions studied

  • Glioblastoma Multiforme

Keywords

  • Glioblastoma Multiforme
  • GBM
  • Btk,
  • CLL
  • Chronic Lymphocytic Leukemia
  • NK
  • Natural Killer (Cells)
  • ORR
  • Overall Response Rate
  • OS
  • Overall Survival
  • RANO
  • Response Assessment in Neuro-oncology (Criteria)
  • RCI
  • Reliale Change Index (methodology)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women ≥18 years of age
  • confirmed GBM at first or second recurrence after concurrent or chemotherapy or radiotherapy (must have received temozolomide).
  • Radiographic demonstration of disease progression by MRI following prior therapy.
  • (bidimensional) as defined by the RANO criteria, with a minimum measurement of 1 cm in longest diameter on MRI performed within 21 days of first dose of acalabrutinib; MRI must have been obtained ≥4 weeks after any salvage surgery after first or second relapse.
  • Stable or decreasing dose of ≥5 days before baseline MRI (at study entry).
  • On a stable dose of any required therapy (such as anticonvulsant medication for subjects to be enrolled into the Phase 1b portion), for ≥3 weeks before the first dose of acalabrutinib.
  • (ECOG) performance status of ≤2.
  • ≥ 12 weeks.
  • Completion of all prior anticancer therapy before first ACP-196 dose.
  • Need to have recovered (i.e., Grade ≤1 or baseline) from AEs associated with prior cancer therapy. Note: Subjects with Grade ≤2 neuropathy or Grade

    • 2 alopecia are an exception, and may qualify for the study.

Exclusion criteria

Exclusion Criteria:

  • Three or more for GBM.
  • Prior (other than GBM), except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer from which the subject has been disease free for ≥2 years. Any cases of prior malignancy allowed on study are to be approved by the study medical monitor.
  • Significant cardiovascular disease.
  • Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel, symptomatic inflammatory bowel disease, partial or complete bowel obstruction, or gastric restrictions and bariatric surgery, such as gastric bypass.
  • Evidence of bleeding diathesis or coagulopathy.
  • Requires urgent palliative intervention for primary disease
  • Requires treatment with a strong inhibitor..
  • History of stroke or intracranial hemorrhage within 6 months before first dose of study drug.
  • Breastfeeding or pregnant.
  • Subjects previously treated with bevacizumab (Avastin)
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Cohort 1

    ACP-196 200 mg administered orally (PO) twice per day (BID)

    Drug: ACP-196

  • Experimental
    Cohort 2

    ACP-196 400mg administered orally (PO) once per day (QD).

    Drug: ACP-196

Interventions

  • Cohort 1: ACP-196 200 mg (PO) twice per day (BID) Cohort 2: ACP-196 400 mg (PO) once per day (QD).

    Also known as: Acalabrutinib.

06

What researchers measure

Primary outcomes

  1. Assessment of Tumor Status for Overall Response Rate With Use of RANO Criteria.

    To evaluate the efficacy of acalabrutinib monotherapy in subjects with recurrent GBM based on overall response rate (ORR) per the Response Assessment in Neuro-oncology (RANO) criteria. Responses are either complete response (CR) or partial response (PR) by RANO.

    Time frame: On Cycle 3 Day 1, Cycle 4 Day 1 (4 weeks after Cycle 3 Day 1 scan to evaluate for response stability), then on Day 1 of every other cycle (every 8 weeks) thereafter (e.g., Cycle 6 Day 1, Cycle 8 Day 1)

07

Results

Posted Jul 29, 2020

Participant flow

Participant flow — Overall Study
MilestoneCohort 1 - AcalabrutinibCohort 2 - Acalabrutinib
Started159
Enrolled159
Received study medication159
Discontinued study149
Completed149
Not completed10

Outcome measures

PrimaryAssessment of Tumor Status for Overall Response Rate With Use of RANO Criteria.

To evaluate the efficacy of acalabrutinib monotherapy in subjects with recurrent GBM based on overall response rate (ORR) per the Response Assessment in Neuro-oncology (RANO) criteria. Responses are either complete response (CR) or partial response (PR) by RANO.

Time frame:
On Cycle 3 Day 1, Cycle 4 Day 1 (4 weeks after Cycle 3 Day 1 scan to evaluate for response stability), then on Day 1 of every other cycle (every 8 weeks) thereafter (e.g., Cycle 6 Day 1, Cycle 8 Day 1)
Reported as:
Count of participants · Participants
Assessment of Tumor Status for Overall Response Rate With Use of RANO Criteria.
ParticipantsCohort 1Cohort 2
Assessment of Tumor Status for Overall Response Rate With Use of RANO Criteria.11

Adverse events

Collected over Reported Adverse Events (AEs) include starting on or after Day 0 and on or before Day 940.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 112/15 (80%)6/15 (40%)15/15 (100%)
Cohort 2 - Acalabrutinib7/9 (77.8%)4/9 (44.4%)9/9 (100%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventCohort 1Cohort 2 - Acalabrutinib
VomitingGastrointestinal disorders2/151/9
InfluenzeInfections and infestations0/151/9
StreptococcalInfections and infestations0/151/9
Decreased AppetiteMetabolism and nutrition disorders0/151/9
Confusional StatePsychiatric disorders0/151/9
Rash MacularSkin and subcutaneous tissue disorders0/151/9
Abdominal PainGastrointestinal disorders1/150/9
Large Intestine PerforationGastrointestinal disorders1/150/9
NauseaGastrointestinal disorders1/150/9
Abdominal InfectionInfections and infestations1/150/9
Most frequent other events
Showing 10 of 100
Most frequent other events
EventCohort 1Cohort 2 - Acalabrutinib
HeadacheNervous system disorders7/155/9
FatigueGeneral disorders6/153/9
NauseaGastrointestinal disorders3/153/9
VomitingGastrointestinal disorders5/153/9
DiarrhoeaGastrointestinal disorders4/152/9
FallInjury, poisoning and procedural complications4/152/9
HemiparesisNervous system disorders4/150/9
TinnitusEar and labyrinth disorders0/152/9
DysphagiaGastrointestinal disorders0/152/9
CD4 Lymphocytes DecreasedInvestigations1/152/9

Baseline characteristics

Age, Continuous
Age, Continuous(Year)Cohort 1Cohort 2Total
Mean58.7 ± 6.7445.7 ± 13.8453.8 ± 11.64
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1Cohort 2Total
Female7411
Male8513
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1Cohort 2Total
Hispanic or Latino011
Not Hispanic or Latino15722
Unknown or Not Reported011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1Cohort 2Total
American Indian or Alaska Native000
Asian101
Native Hawaiian or Other Pacific Islander000
Black or African American000
White13821
More than one race000
Unknown or Not Reported112
Region of Enrollment
Region of Enrollment(Participants)Cohort 1Cohort 2Total
United States15924
08

Study locations

7 sites
  • Research Site
    Los Angeles, California 90095-1769, United States
  • Research Site
    Palo Alto, California 94304, United States
  • Research Site
    Boston, Massachusetts 02114, United States
  • Research Site
    Boston, Massachusetts 02215, United States
  • Research Site
    Boston, Massachusetts 2215, United States
  • Research Site
    New York, New York 10021, United States
  • Research Site
    Vancouver, Washington 98684, United States
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2016 to primary completion in Jun 2020, 53 months.

Results were first posted in Jul 2020, 1 month after primary completion.

Of 53 industry-sponsored phase 1/2 interventional studies under Glioblastoma, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 75. This study's 53 months is close to that.

Counting every sponsor, half of 138 studies reached it within 68 months; a quarter within 47 and three quarters within 102.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2015
First posted
Oct 27, 2015
StartActual
Jan 25, 2016
Primary completionActual
Jun 26, 2020
CompletionEst.
Apr 1, 2026
Results first posted
Jul 29, 2020
Last update
Mar 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02586857
Lead sponsor
Acerta Pharma BV
Responsible party
Sponsor
First posted
Oct 27, 2015
Start date
Jan 25, 2016
Primary completion
Jun 26, 2020
Completion
Apr 1, 2026 (estimated)
Results posted
Jul 29, 2020
Last update
Mar 25, 2026

Study contacts

Acerta Clinical Trials
study director · 1-888-292-9613; acertamc@dlss.com

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acalabrutinib

Start the discussion